Singapore markets closed

LLY Jan 2026 480.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
17.000.00 (0.00%)
As of 10:00AM EDT. Market open.
Full screen
Previous close17.00
Open17.00
Bid0.00
Ask0.00
Strike480.00
Expiry date2026-01-16
Day's range17.00 - 17.00
Contract rangeN/A
Volume1
Open interest41
  • Reuters

    UPDATE 2-Eli Lilly's weight-loss drug succeeds in trials with sleep apnea patients

    Weight-loss drugs such as Lilly's Zepbound and Novo Nordisk's Wegovy, called GLP-1 agonists, have already brought in billions of dollars in sales as treatments for obesity and diabetes. Lilly's trial results add to a growing body of clinical evidence that suggests GLP-1 drugs have medical benefits beyond diabetes and weight loss. Novo's Wegovy was approved by the FDA in March as a treatment for lowering the risk of stroke and heart attack in overweight or obese adults who do not have diabetes.

  • PR Newswire

    Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity

    Eli Lilly and Company (NYSE: LLY) today announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints. Percentage change in AHI was a key secondary endpoint in both studies. AHI records the number of times a person's breathing shows a restricted or complete block of airflow per hour of sleep and is used to evaluate the sever

  • Zacks

    Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts

    In the closing of the recent trading day, Eli Lilly (LLY) stood at $749.26, denoting a -0.2% change from the preceding trading day.